Triphasic Birth Control Options
For a healthy woman seeking hormonal birth control, triphasic combined oral contraceptives are available formulations that vary hormone doses across three phases of the pill pack, though they offer no significant clinical advantage over monophasic pills in terms of efficacy, safety, or side effects.
Available Triphasic Formulations
The primary triphasic COCs contain ethinyl estradiol (0.025-0.040 mg/day) combined with various progestins in three different dose phases throughout the cycle 1. Common formulations include:
- Levonorgestrel-based triphasics (e.g., Triphasil, Triquilar): These contain varying doses of levonorgestrel (0.05-0.15 mg) across three phases 2
- Norethindrone-based triphasics (e.g., Ortho 7/7/7, Tri-Norinyl): These use norethindrone in graduated doses 3, 4
- Newer progestin triphasics: Formulations with desogestrel, gestodene, or norgestimate 1
Clinical Performance
Efficacy is excellent across all triphasic formulations, with typical-use failure rates of approximately 9% annually, comparable to other combined hormonal contraceptives 5. The triphasic design was originally developed to more closely mimic natural menstrual cycles and reduce total hormone exposure 3.
Cycle Control and Side Effects
The evidence shows:
- Breakthrough bleeding occurs in only 1.9% of cycles with triphasic pills, which is remarkably low 6
- Newer progestin triphasics (desogestrel, gestodene, norgestimate) demonstrate better cycle control and fewer androgenic side effects compared to levonorgestrel or norethindrone formulations 1
- Common side effects include breast tenderness (21% of women, though often resolves within 3 months), weight changes (3%), nausea (3.7%), and headaches (3.2%) 6
- The choice of progestin appears more important than the phasic regimen in determining bleeding patterns 4
Comparison to Monophasic Pills
Triphasic and monophasic COCs have essentially equivalent risk-benefit profiles 1. Both formulations:
- Have minimal effects on carbohydrate and lipid metabolism
- Carry comparable low risks of coronary heart disease
- Provide identical non-contraceptive benefits (reduced ovarian/endometrial cancer, decreased menstrual blood loss, protection against PID)
- Show similar overall side effect profiles
The theoretical advantage of lower total hormone exposure with triphasics has not translated into clinically meaningful differences in safety or tolerability 1.
Initiation Guidelines
Following U.S. Selected Practice Recommendations 5:
- Start within 5 days of menstrual bleeding: No backup contraception needed
- Start >5 days after bleeding begins: Use backup contraception for 7 days
- Can initiate anytime if reasonably certain the woman is not pregnant
Important Contraindications
Based on guideline evidence 7:
Absolute contraindications:
- Smoking >15 cigarettes/day in women ≥35 years old
- Personal history of arterial events (MI, stroke)
- Uncontrolled hypertension
- First 3 weeks postpartum (VTE risk)
Relative contraindications:
- Smoking in women <35 years (acceptable if no other cardiovascular risk factors)
- Controlled hypertension in women <35 years without complications
- Weeks 4-6 postpartum in breastfeeding women
Clinical Bottom Line
For a healthy woman without contraindications, any triphasic COC is an appropriate choice, with selection based primarily on progestin type rather than the triphasic regimen itself. Formulations containing newer progestins (desogestrel, gestodene, norgestimate) may offer marginally better cycle control and fewer androgenic effects 1. However, the overall clinical differences between triphasic and monophasic pills are minimal, so the choice should be guided by availability, cost, and patient preference rather than any perceived superiority of the triphasic design.